Sustained Release from Ionic-Gradient Liposomes Significantly Decreases ETIDOCAINE Cytotoxicity
- 136 Downloads
Etidocaine (EDC) is a long lasting local anesthetic, which alleged toxicity has restricted its clinical use. Liposomes can prolong the analgesia time and reduce the toxicity of local anesthetics. Ionic gradient liposomes (IGL) have been proposed to increase the upload and prolong the drug release, from liposomes.
First, a HPLC method for EDC quantification was validated. Then, large unilamellar vesicles composed of hydrogenated soy phosphatidylcholine:cholesterol with 250 mM (NH4)2SO4 - inside gradient - were prepared for the encapsulation of 0.5% EDC. Dynamic light scattering, nanotracking analysis, transmission electron microscopy and electron paramagnetic resonance were used to characterize: nanoparticles size, polydispersity, zeta potential, concentration, morphology and membrane fluidity. Release kinetics and in vitro cytotoxicity tests were also performed.
IGLEDC showed average diameters of 172.3 ± 2.6 nm, low PDI (0.12 ± 0.01), mean particle concentration of 6.3 ± 0.5 × 1012/mL and negative zeta values (−10.2 ± 0.4 mV); parameters that remain stable during storage at 4°C. The formulation, with 40% encapsulation efficiency, induced the sustained release of EDC (ca. 24 h), while reducing its toxicity to human fibroblasts.
A novel formulation is proposed for etidocaine that promotes sustained release and reduces its cytotoxicity. IGLEDC can come to be a tool to reintroduce etidocaine in clinical use.
KEY WORDSdrug-delivery etidocaine ionic gradient liposomes local anesthesia
Drug delivery system
Dynamic light scattering
Electron paramagnetic resonance
Hydrogenated soy phosphatidylcholine
Half maximal inhibitory concentration of cell viability
Ionic gradient liposomes
Etidocaine-containing sulphate gradient liposomes
Large unilamellar vesicle
Transmission electron microscopy
- 4.Covino BG, Vassalo HG. Local anesthetics: mechanisms of action and clinical use. Rio de Janeiro: Colina Editora; 1985.Google Scholar
- 5.Garciat DG. Etidocaine - a long-acting anesthestic agent: review of the literature. Anesth Prog. 1972;29(1):12–3.Google Scholar
- 7.Discontinued Drug Product List. US food and drug administration. Docket n° 2008-P-0527. September 25th, 2008. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=017751. Acessed March 02, 2018.
- 8.Determination that Duranest® (etidocaine hydrochloride) injection, 0.5%, and five other Duranest® drug products were not withdrawn from sale for reasons of safety or effectiveness. FR. Federal Register / Vol. 77, No. 49 / March 13th, 2012 / Notices T. Vol. 77. 2012.Google Scholar
- 12.de Paula E, Cereda CMS, Fraceto LF, de Araújo DR, Franz-Montan M, Tofoli GR, et al. Micro and nanosystems for delivering local anesthetics. Expert Opin Drug Deliv. 2012;9(12):1505–24.Google Scholar
- 15.da Silva CMG, Franz-Montan M, Limia CEG, Ribeiro LN de M, Braga MA, Guilherme VA, et al. Encapsulation of ropivacaine in a combined (donor-acceptor, ionic-gradient) liposomal system promotes extended anesthesia time. PLoS One. 2017;12(10):1–16.Google Scholar
- 16.Barenholz Y, Haran G. Method of amphiphatic drug loading in liposome by amonium ion gradient. US Patent. 1994;5:316–771.Google Scholar
- 22.ICH. Validation of analytical procedures: text and methodology Q2(R1). Geneva: Intl Conf. Harmon; 2005.Google Scholar
- 25.Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470–5.Google Scholar
- 34.Mohanraj V, Chen Y, Chen M. Nanoparticles – a review. Trop J Pharm Res Trop J Pharm Res. 2006;5(1):561–73.Google Scholar
- 36.Fraceto LF, Spisni A, Schreier S, de Paula E. Differential effects of uncharged aminoamide local anesthetics on phospholipid bilayers, as monitored by 1H-NMR measurements. Biophys Chem. 2005;115(1):11–8.Google Scholar
- 41.Yeagle PL. The structure of biological membranes. 3rd ed. Boca Raton: CRC Rress; 2012.Google Scholar